Skip to content
INVESTIGATORS NETWORK
Our team is comprised of physicians with extensive experience in clinical research who work to ensure the best care for their patients.
GASTROINTESTINAL ONCOLOGY & HEREDITARY CANCER

Marcia Cruz Correa, MD, PhD, AGAF, FASGE

HEMATOLOGY-ONCOLOGY

Karina Arocho González, MD
Luis Delgado, MD
María V. García Pallas, MD
Omayra González, MD
José Ortega, MD
Noridza Rivera Rodríguez, MD
José Sobrino Catoni, MD
Elías Sobrino Najul, MD

UROLOGY

Eduardo Canto, MD
Antonio Puras, MD
Gilberto Ruiz Deya, MD
Ricardo Sánchez-Ortiz, MD

GASTROENTEROLOGY

Kermit Richiez, MD
José Rivera Acosta, MD
Suzette Rivera MacMurray, MD
Artemio Santiago, MD

RADIATION ONCOLOGY

Roberto Santiago, MD

DERMATOLOGY

Hiram Ruiz, MD

AFFILIATED ONCOLOGY TEAM:

Santa E. Merle Ramírez, MD
Adelaida Ortiz, MD
Ana Cecilia Salas, PsyD, MSc

ENROLLING STUDIES

GENETIC TESTING

With the promise of precision medicine becoming a reality, genetic testing has become the standard of care for many cancer types– and required for certain therapies. More than ever, oncologists need a trusted profiling partner to provide reliable, high quality molecular information to guide precise and individualized treatment decisions.
PROACTIVE GENETIC TESTING
Proactive genetic testing for healthy and individuals with personal or family history of cancer. Genetic tests for healthy adults who want to understand their DNA and focus on cancer prevention.

  • Genetic testing for individuals with cancer might provide information to understand the cause for the development of cancer.
  • Testing for known familial genetic mutations provides information about cancer risk, as well as potential therapeutic options.
  • Proactive genetic testing offers healthy adults without a strong personal or family history of cancer an opportunity to learn about how their genes could potentially impact their health.
  • Proactive genetic testing offers testing options that analyze genes that are well-established indicators of a significantly increased risk of developing hereditary cancers, cardiovascular conditions, and other medically important disorders.
  • Our diagnostic-grade tests are performed in a CLIA- and CAP-certified laboratory and reviewed by our team of Ph.D. scientists, lab directors, and board-certified oncologists.

COMPREHENSIVE TUMOR PROFILING
This technology approach allows our medical teams to decode cancer and more fully understand the biology of the tumor – therefore helping oncologists’ better plan their attack.

  • Next-Generation Sequencing (NGS): rapidly examines and more broadly detects DNA mutations, copy number variations and gene fusions across the genome
  • Immunohistochemistry (IHC): determines level of protein expression
  • In situ Hybridization: detects gene deletions, amplifications, translocations and fusions
  • Sanger Sequencing: examines strands of DNA to identify mutations by analyzing long contiguous sequencing reads
  • Pyro Sequencing (PyroSeq): detects and quantifies mutations, methylation, etc. through sequencing by synthesis
  • Fragment Analysis (FA/Frag. Analysis): detects changes in DNA or RNA to indicate the presence or absence of genetic marker

MINIMAL RESIDUAL DISEASE (MDR) ASSESSMENT AND TREATMENT MONITORING
Personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for cancer management.

  • Highly accurate MRD testing uniquely personalized to each patient’s tumor mutation signature
  • Highly sensitive non-invasive assay to detect MRD earlier than other standard of care clinical tools
  • Earlier cancer recurrence monitoring to help inform adjuvant treatment decisions
  • Custom-built for each patient, using tumor tissue from surgical resection
  • Highest level of monitoring accuracy when determining whether to augment or reduce therapy
QUICK REFERENCE GUIDE